[1]俞 婷,刘娜娜,钟 青,等.沙库巴曲缬沙坦与传统血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂治疗阵发性房颤疗效对比观察[J].陕西医学杂志,2023,52(10):1407-1410.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.028]
　YU Ting,LIU Nanna,ZHONG Qing,et al.Comparison in efficacy of sacubitril/valsartan and traditional ACEI/ARB in patients with paroxysmal atrial fibrillation[J].,2023,52(10):1407-1410.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.028]
点击复制

沙库巴曲缬沙坦与传统血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂治疗阵发性房颤疗效对比观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年10期
页码:
1407-1410
栏目:
药物与临床
出版日期:
2023-10-05

文章信息/Info

Title:
Comparison in efficacy of sacubitril/valsartan and traditional ACEI/ARB in patients with paroxysmal atrial fibrillation
作者:
俞 婷1; 刘娜娜1; 钟 青1; 苏 涛2
(1.解放军联勤保障部队第908医院心血管内科,江西 南昌 330001; 2.空军军医大学第一附属医院心血管内科,陕西 西安 710032)
Author(s):
YU Ting; LIU Nanna; ZHONG Qing; SU Tao
(Department of Cardiovascular Medicine,the 908 Hospital of Joint Logistic Support Force of PLA,Nanchang 330001,China)
关键词:
沙库巴曲缬沙坦;  血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂;  心衰;  心房颤动;  左房内径;  左房容积
Keywords:
Sacubitril/valsartan;  Angiotensin converting enzyme inhibitor/angiotensin receptor blockers;  Heart failure;  Atrial fibrillation;  Left atrial diameter;  Left atrial volume
分类号:
R 541.7
DOI:
DOI:10.3969/j.issn.1000-7377.2023.10.028
文献标志码:
A
摘要:
目的: 观察沙库巴曲缬沙坦对比传统血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂(ACEI/ARB)在阵发性房颤患者中的疗效。方法: 选取诊断为阵发性房颤患者共100例,随机分为沙库巴曲缬沙坦组50例及ACEI/ARB组50例,治疗时间均为1年。观察两组治疗后1年房颤复发率、左房内径、左房容积、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、N末端脑利钠肽前体(NT-proBNP)、再住院率。结果:患者在用药过程中出现心慌、气短等症状立即做心电图或24 h动态心电图,沙库巴曲缬沙坦组与ACEI/ARB组房颤发生率分别为10%与36%,比较差异有统计学意义(均P<0.05); 沙库巴曲缬沙坦组与ACEI/ARB组比较,左房内径、左房容积、LVEDD降低,LVEF值升高,差异有统计学意义(均P<0.05)。沙库巴曲缬沙坦组NT-proBNP下降更明显; 沙库巴曲缬沙坦组再住院率低于ACEI/ARB组(10% 与34%,P<0.05),沙库巴曲缬沙坦组有7例出现血压偏低,药物减量后仍能坚持服药。结论:沙库巴曲缬沙坦与传统ACEI/ARB比较可以降低房颤复发率,改善心功能,降低再住院率。
Abstract:
Objective:To compare the efficacy of sacubitril/valsartan and traditional angiotensin converting enzyme inhibitor/angiotensin receptor blockers(ACEI/ARB)in patients with paroxysmal atrial fibrillation.Methods:A total of 100 patients with paroxysmal atrial fibrillation were randomly divided into sacubitril/valsartan group(50 cases)and ACEI/ARB group(50 cases).The treatment time was 1 year.The recurrence rate of atrial fibrillation,left atrial diameter,left atrial volume,left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),forebrain natriuretic peptide(NT-proBNP)and rehospitalization rate one year after treatmentwere observed in the two groups.Results:Electrocardiogram or 24-hour dynamic electrocardiogram was performed immediately when patients had symptoms such as palpitation and shortness of breath during the medication.The incidence of atrial fibrillation in sacubitril/valsartan group and ACEI/ARB group was 10% and 36%,respectively,and the difference was statistically significant(P<0.05).Compared with ACEI/ARB group,left atrial diameter,left atrial volume and LVEDD were decreased,and LVEF was increased in sacubitril/valsartan group(all P<0.05).The decrease of NT-proBNP in sacubitril/valsartan group was more significant.The rehospitalization rate of sacubitril/valsartan group was lower than that of ACEI/ARB group(10% vs.34%,P<0.05).Seven patients in sacubitril/valsartan group had low blood pressure,but could still adhere to medication after drug reduction.Conclusion:Compared with ACEI/ARB,Sacubitril/valsartan can reduce the recurrence rate of atrial fibrillation,improve cardiac function,and reduce the rehospitalization rate.

参考文献/References:

[1] Packer M,Pitt B,Rouleau JL,et al.Long-term effects of flosequinan on the morbidity and mortality of patients with severe chronic heart failure:Primary results of the PROFILE trial after 24 years[J].JACC Heart Fai,2017:399-407.
[2] Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults:National implications for rhythm management and stroke prevention:The AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA)study[J].Jama,2001,285(18):2370-2375.
[3] Kühnlein P,Mahnkopf C,Majersik JJ,et al.Atrial fibrosis in embolic stroke of undetermined source:A multicenter study[J].European Journal of Neurology,2021,28(11):3634-3639.
[4] Lou Q,Liu G,Lv J,et al.Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J].European Journal of Pharmacology,2020,881:173120.
[5] Ouwerkerk W,Voors AA,Anker SD,et al.Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure:A prospective European study[J].European Heart Journal,2017,38(24):1883-1890.
[6] Voors AA,Anker SD,Cleland JG,et al.A systems BIOlogy study to tailored treatment in chronic heart failure:Rationale,design,and baseline characteristics of BIOSTAT-CHF[J].European Journal of Heart Failure,2016,18(6):716-726.
[7] Owens AT,Susan Br,Mariell J.Neprilysin inhibitors:emerging therapy for heart failure[J].Annual Review of Medicine,2017,(68):41-49.
[8] Ramanathan K,Padmanabhan G.Soluble neprilysin:A versatile biomarker for heart failure,cardiovascular diseases and diabetic complications:A systematic review[J].Indian Heart Journal,2020,72(1):14-19.
[9] Solomon SD,McMurray JJV,Anand IS,et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J].New England Journal of Medicine,2019,381(17):1609-1620.
[10] DeVore AD,Braunwald E,Morrow DA,et al.Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure:Secondary analysis of the open-label extension of the PIONEER-HF trial[J].JAMA Cardiology,2020,5(2):202-207.
[11] 羡微微,刘桂清.沙库巴曲缬沙坦对射血分数降低性心衰患者血浆去甲肾上腺素和血清心肌肌钙蛋白I水平的影响研究[J].陕西医学杂志,2020,49(10):1306-1309.
[12] 陈 莉,逯伟达,吴媛媛,等.沙库巴曲缬沙坦对射血分数降低的心力衰竭 Ⅳ 级患者生化指标和左心室结构的干预作用[J].中华老年医学杂志,2019,38(5):525-528.
[13] Santangelo G,Bursi F,Toriello F,et al.Sacubitril/valsartan improves medium-term reverse left ventricular remodeling:Why wait?[J].Journal of Cardiovascular Medicine,2019,20(10):727-729.
[14] 马红红,马艳梅.心宝丸联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床研究[J].现代药物与临床,2023,38(1):110-115.
[15] Lou Q,Liu G,Lv J,et al.Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J].European Journal of Pharmacology,2020,881:173120.
[16] De-Vecchis R,Paccone A,Di-Maio M.Favorable effects of sacubitril/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation:A retrospective cohort study[J].Journal of Clinical Medicine Research,2020,12(2):100.
[17] Kristensen SL,Jhund PS,Mogensen UM,et al.Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation[J].Circulation:Heart Failure,2017,10(10):e004409.
[18] Chua W,Law JP,Cardoso VR,et al.Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform:A validation study[J].PLoS Medicine,2021,18(2):e1003405.
[19] Santema BT,Chan MY,Tromp J,et al.The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure[J].Clinical Research in Cardiology,2020,109(3):331-338.
[20] Solomon SD,Mcmurray JJV,Anand IS,et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J].New England Journal of Medicine,2019,381(17):1609-1620.

备注/Memo

备注/Memo:
基金项目:江西省自然科学基金青年基金资助项目(20181BAB215031); 江西省卫生健康委员会普通科技计划项目(20204798)
更新日期/Last Update: 2023-10-07